Your selection
Innovation / 12.05.2026
Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.
1st Quarter 2026:
- Sales of €72.9 million (previous year: €68.2 million)
- EBIT before special items of €16.0 million (previous year: €16.2 million)
- Net income of €10.4 Mio. (previous year: €9.7 million)
Forecast 2026:
- Sales of around €320 million (confirmed)
- EBIT before special items of around €80 million (confirmed)
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year. Due to a slightly weaker product mix in the Isotope Products segment during the first two months of the year, adjusted Group EBIT decreased by 2% to €16.0 million. Net income increased by 7% to €10.4 million, or €0.17 per share.
Sales in the Medical segment were significantly higher in the first three months of the year at €41.5 million compared to the previous year (€34.4 million). The pharmaceutical radioisotope business remains the most important revenue driver. In particular, the development of sales of generators and in the Contract Manufacturing & Development (CDMO) segment is worth noting.
The Isotope Products segment generated sales of €31.5 million, which was €2.3 million, or approximately 7%, lower than in the first three months of the previous year. A strong fourth quarter of 2025 was followed by a subdued start to the year, which regained significant momentum in March.
The forecast for fiscal year 2026, published on 26 March 2026, remains unchanged. The Executive Board continues to anticipate revenue of approximately €320 million and adjusted EBIT of approximately €80 million.
The complete quarterly report can be viewed here: https://www.ezag.com/Q12026en
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Overview News
News Buch Berlin
Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year.
more ...First Joint Career Day Brings Science and Industry Together
The Max Delbrück Center’s Career Day, held in cooperation with the operator of the Berlin-Buch Campus, offered young researchers insights into the working world of startups and biotech companies
more ...A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly int...
more ...Events Buch Berlin
12.05.2026, 18:00
Info-Veranstaltung zur Neubauplanung in Karow
Die Senatsverwaltung für Stadtentwicklung, Bauen und Wohnen lädt Interessierte zu einer öffentlichen Informationsveranstaltung ins ehemalige Kulturhaus an der Grundschule Alt-Karow ein
more ...13.05.2026, 09:00
Hufeland-Tag "Fit for Life" mit Sport und Grünem Klassenzimmer
13.05.2026, 17:00
Frühlingskonzert auf dem Campus Berlin-Buch
Der Freundeskreis des Max Delbrück-Centers lädt gemeinsam mit der Klavierprofessorin Galina Iwanzowa-Bielka erneut zu einem Frühlingskonzert mit jungen Talenten ein. Veranstaltungsort ist traditionell...
more ...